Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors.

Journal article

PURPOSE: Preclinical studies show that OXi4503 (combretastatin A1 diphosphate, CA1P) is more potent than other clinically evaluated vascular-disrupting agents. EXPERIMENTAL DESIGN: Escalating doses of OXi4503 were given intravenously over 10 minutes on days 1, 8, and 15 every 28 days to patients with advanced solid tumors. RESULTS: Doses were escalated in single-patient cohorts from 0.06 to 1.92 mg/m(2), then expanded cohorts to 15.4 mg/m(2) in 43 patients. Common adverse drug reactions were...

Expand abstract

Authors: Patterson, D; Zweifel, M; Middleton, MR; Price, P; Folkes, L

• Publication status: Published
• Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
• Volume: 18
• Issue: 5
• Pages: 1415-1425
• Publication date: 2012-03-01
• DOI: 10.1158/1078-0432.ccr-11-2414
• EISSN: 1557-3265
• ISSN: 1078-0432
• Language: English
• Keywords: Neoplasms; Humans; Young Adult; Treatment Outcome; Adult; Middle Aged; Aged; Female; Male; Magnetic Resonance Imaging; Antineoplastic Agents; Diphosphates; Angiogenesis Inhibitors; Stilbenes